I-Mab

•

the timing of initiation and completion, and the progress of our drug discovery and research programs;

•

the timing and likelihood of regulatory filings and approvals;

•

our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;

•

the approval, pricing and reimbursement of our drug candidates;

•

the commercialization of our drug candidates;

•

the market opportunities and competitive landscape of our drug candidates;

•

the payment, receipt and timing of any milestone payments in relation to the licensing agreements;

•

estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;

•

our ability to attract and retain senior management and key employees;

•

•

the expected impact of global business, political and macroeconomic conditions, including inflation, interest rate fluctuations and volatile market conditions, instability in the global banking system, and global events, including regional conflicts around the world, on our business, clinical trials, financial condition, liquidity and results of operations;

•

future developments, trends, conditions and competitive landscape in the industry and markets in which we operate;

•

our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans, objectives and goals;

•

our ability to obtain and maintain protection of intellectual property for our technology and drug candidates;

•

the rate and degree of market acceptance and clinical utility of our drug candidates;

•

our ability to identify and integrate suitable acquisition targets;

•

changes to regulatory and operating conditions in our industry and markets;

•

the expected contingent consideration to be received from TJ Biopharma based on the achievement of certain future regulatory and sales based milestone events; and

•

the expected decrease of our research and development expenses and administrative expenses in the near future due to the divestiture of our Greater China assets and business operations, the strategic reprioritization of our drug candidates, and our internal restructuring in 2025.